AGP Executive Report
Last update: 2 hours agoMedicaid Fraud Crackdown: Three people were convicted and sentenced in Kentucky for nearly $5M in Medicaid/Medicare fraud tied to addiction treatment clinics, including billing for services not provided and using a doctor’s DEA credentials to prescribe Suboxone. Patient Safety & Recalls: The FDA classified a nationwide Levothyroxine recall as Class II due to subpotency, listing multiple affected lots and expiration dates. New ADHD Option: Otsuka’s Simtriyo (centanafadine) won FDA approval for ADHD in adults and children 6+, with availability expected later this year after controlled-substance scheduling. Clinical Care in Primary Settings: A large trial in JAMA Pediatrics found family-based childhood obesity treatment can work in primary care practices, with meaningful weight improvements lasting at least 18 months. Health System Access Pressure: New York hospitals and UnitedHealthcare are again facing an Aug. 1 deadline for contract talks, with patients already at risk of being out of network. Public Health Preparedness: Canada announced a new medical countermeasures lab facility in Winnipeg. Bioelectronics Breakthrough: Feinstein Institutes released a comprehensive human vagus nerve anatomical map to support neuromodulation research. Rural Transport Strain: Colorado Medicaid non-emergency medical transportation cuts are reducing ride options for rural patients.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
